Clinic
Jackson Hospital Corporation
Jackson Hospital Corporation was paid $34.90M by Medicaid between Jan 2018 and Dec 2024, across 256 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoJACKSON HOSPITAL CORPORATION
JACKSON, KY 41339
JACKSON, KY 41339
33aNPI1346247962assigned 06/29/2005
33bProvider typeCritical Access Hospital Clinic/Center
28Total paid$34.90M
24GClaims928,056
24DCodes billed256
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 160,682 | $5.20M | |
| 2019 | 158,913 | $6.27M | |
| 2020 | 138,934 | $4.63M | |
| 2021 | 150,287 | $5.05M | |
| 2022 | 119,123 | $5.02M | |
| 2023 | 124,489 | $4.86M | |
| 2024incomplete | 75,628 | $3.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 30,837 | 21,038 | $7.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 32,833 | 25,722 | $5.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 17,450 | 6,668 | $4.78M |
| 41899 | Unlisted procedure, dentoalveolar structures | 6.6% | 1,349 | 1,257 | $2.29M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.2% | 9,218 | 5,662 | $2.17M |
| 0240U | 2.7% | 8,898 | 6,739 | $933K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 6,559 | 4,126 | $858K |
| 80074 | 2.0% | 16,046 | 12,748 | $689K | |
| 71045 | Radiologic examination, chest; single view | 1.8% | 23,436 | 10,100 | $629K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 6,466 | 5,027 | $591K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 12,330 | 10,021 | $501K |
| 80053 | Comprehensive metabolic panel | <1% | 68,740 | 41,766 | $331K |
244 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,961 | $329K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,498 | $301K |
| G0378 | Hospital observation service, per hour | <1% | 2,767 | $295K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,703 | $290K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 987 | $290K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,458 | $273K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,034 | $265K |
| 36415 | Collection of venous blood by venipuncture | <1% | 75,117 | $262K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,695 | $248K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14,800 | $245K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,743 | $242K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,256 | $228K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,055 | $215K |
| 80061 | Lipid panel | <1% | 19,184 | $212K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,904 | $190K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,025 | $179K |
| 71250 | <1% | 1,953 | $169K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,138 | $146K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,106 | $140K |
| 72100 | <1% | 3,663 | $138K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,936 | $125K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,669 | $124K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,030 | $123K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,104 | $121K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,382 | $120K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 20,306 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,240 | $111K |
| J3490 | Unclassified drugs | <1% | 45,262 | $108K |
| 82805 | <1% | 4,160 | $96K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,134 | $94K |
| 83880 | <1% | 7,211 | $89K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,004 | $87K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 5,401 | $75K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,548 | $71K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,562 | $71K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 3,366 | $67K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,677 | $62K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,689 | $54K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 205 | $52K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,611 | $52K |
| 82607 | <1% | 4,178 | $49K | |
| 73562 | <1% | 2,017 | $44K | |
| 82803 | <1% | 5,583 | $44K | |
| 86592 | <1% | 14,373 | $43K | |
| 76536 | <1% | 523 | $43K | |
| 73030 | <1% | 2,108 | $43K | |
| 84484 | <1% | 9,371 | $41K | |
| 96376 | <1% | 1,965 | $40K | |
| 93971 | <1% | 452 | $39K | |
| 83735 | <1% | 11,745 | $37K | |
| 36600 | <1% | 8,250 | $35K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 391 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,613 | $33K |
| 82553 | <1% | 8,054 | $32K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,255 | $32K |
| 87040 | <1% | 6,208 | $32K | |
| 81001 | <1% | 17,261 | $31K | |
| 72040 | <1% | 1,017 | $31K | |
| 84703 | <1% | 5,540 | $29K | |
| 73610 | <1% | 1,307 | $29K | |
| 82746 | <1% | 2,332 | $28K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 417 | $28K |
| 74018 | <1% | 1,377 | $27K | |
| 97161 | <1% | 434 | $27K | |
| 73630 | <1% | 1,290 | $26K | |
| 82728 | <1% | 2,193 | $25K | |
| 73130 | <1% | 1,072 | $25K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 204 | $23K |
| 86677 | <1% | 1,768 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 208 | $21K |
| 83690 | <1% | 7,280 | $21K | |
| 82550 | <1% | 8,157 | $20K | |
| 73110 | <1% | 726 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,590 | $20K |
| 82375 | <1% | 4,379 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,169 | $18K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,125 | $17K |
| 83605 | <1% | 4,060 | $17K | |
| 84439 | <1% | 1,524 | $17K | |
| 82150 | <1% | 6,053 | $17K | |
| 72131 | <1% | 124 | $16K | |
| 70486 | <1% | 120 | $16K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 82 | $16K |
| 97035 | <1% | 1,029 | $16K | |
| 87077 | <1% | 4,194 | $15K | |
| 87186 | <1% | 2,771 | $15K | |
| 85027 | <1% | 3,499 | $14K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,096 | $14K |
| 83540 | <1% | 2,346 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 101 | $13K |
| 83050 | <1% | 4,361 | $12K | |
| 83992 | <1% | 2,342 | $11K | |
| 81025 | <1% | 2,742 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,803 | $10K |
| 87634 | <1% | 628 | $9K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 26 | $8K |
| 87070 | <1% | 1,450 | $8K | |
| 87807 | <1% | 777 | $7K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,537 | $7K |
| 72072 | <1% | 130 | $6K | |
| 84702 | <1% | 616 | $6K | |
| 82962 | <1% | 3,459 | $6K | |
| 12001 | <1% | 165 | $5K | |
| 73560 | <1% | 159 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,282 | $5K |
| 73090 | <1% | 245 | $5K | |
| 73590 | <1% | 200 | $5K | |
| 85610 | <1% | 2,157 | $5K | |
| 80326 | <1% | 1,256 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 16 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,907 | $4K |
| 73620 | <1% | 230 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,925 | $4K |
| 73080 | <1% | 166 | $4K | |
| 80355 | <1% | 1,671 | $4K | |
| 86376 | <1% | 277 | $4K | |
| 80171 | <1% | 212 | $4K | |
| 73502 | <1% | 175 | $4K | |
| 85018 | <1% | 4,429 | $4K | |
| 80347 | <1% | 1,646 | $4K | |
| 73521 | <1% | 143 | $4K | |
| 80373 | <1% | 1,676 | $4K | |
| 80365 | <1% | 1,672 | $4K | |
| 80361 | <1% | 1,673 | $4K | |
| 80348 | <1% | 1,672 | $4K | |
| 80354 | <1% | 1,670 | $3K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,447 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 990 | $3K |
| 80050 | General health panel | <1% | 176 | $3K |
| 86140 | <1% | 1,005 | $3K | |
| 80366 | <1% | 1,672 | $3K | |
| 86003 | <1% | 113 | $3K | |
| 80358 | <1% | 1,672 | $3K | |
| 85730 | <1% | 1,074 | $3K | |
| 80353 | <1% | 1,670 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,089 | $2K |
| 80359 | <1% | 1,672 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,393 | $2K |
| 90714 | <1% | 501 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 547 | $2K |
| 94760 | <1% | 702 | $2K | |
| 93017 | <1% | 12 | $2K | |
| 80324 | <1% | 1,686 | $2K | |
| 93970 | <1% | 14 | $2K | |
| 82140 | <1% | 265 | $2K | |
| 73120 | <1% | 85 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,543 | $2K |
| 74022 | <1% | 77 | $2K | |
| 84403 | <1% | 70 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 811 | $2K |
| 72170 | <1% | 143 | $2K | |
| 77080 | <1% | 40 | $2K | |
| 97166 | <1% | 22 | $2K | |
| 80331 | <1% | 758 | $1K | |
| 36416 | <1% | 1,406 | $1K | |
| 96367 | <1% | 42 | $1K | |
| 80364 | <1% | 758 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,365 | $1K |
| 85651 | <1% | 524 | $1K | |
| 12002 | <1% | 56 | $1K | |
| 82248 | <1% | 678 | $1K | |
| 80362 | <1% | 628 | $1K | |
| 80337 | <1% | 786 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 27 | $1K |
| 80334 | <1% | 758 | $1K | |
| 84481 | <1% | 82 | $1K | |
| 80372 | <1% | 758 | $1K | |
| 80369 | <1% | 628 | $1K | |
| 80367 | <1% | 758 | $1K | |
| 80370 | <1% | 758 | $1K | |
| 71101 | <1% | 44 | $1K | |
| 80344 | <1% | 758 | $1K | |
| 80368 | <1% | 758 | $1K | |
| 80338 | <1% | 758 | $1K | |
| 71271 | <1% | 12 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 615 | $1K |
| 80341 | <1% | 758 | $1K | |
| 82785 | <1% | 64 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,622 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 49 | $1K |
| 80357 | <1% | 758 | $974.90 | |
| 85379 | <1% | 389 | $936.77 | |
| 80377 | <1% | 758 | $858.07 | |
| 80371 | <1% | 758 | $818.30 | |
| 80360 | <1% | 758 | $818.30 | |
| 80299 | <1% | 52 | $797.85 | |
| 84153 | <1% | 77 | $788.96 | |
| 76770 | <1% | 13 | $750.76 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 333 | $736.22 |
| 84550 | <1% | 200 | $728.31 | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 197 | $707.41 |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $651.20 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 753 | $634.10 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $621.39 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $621.39 |
| 73140 | <1% | 29 | $619.00 | |
| 86757 | <1% | 37 | $602.53 | |
| 82043 | <1% | 100 | $584.13 | |
| 84100 | <1% | 359 | $564.31 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,713 | $547.82 |
| 85652 | <1% | 351 | $537.78 | |
| 83550 | <1% | 71 | $536.81 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 24 | $517.66 |
| 82570 | <1% | 122 | $515.39 | |
| 84482 | <1% | 31 | $483.58 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 292 | $430.14 |
| 86618 | <1% | 41 | $426.22 | |
| 82670 | <1% | 12 | $379.94 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 311 | $375.91 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 458 | $369.03 |
| 73600 | <1% | 36 | $335.95 | |
| 84402 | <1% | 12 | $314.28 | |
| 80164 | <1% | 53 | $292.64 | |
| 83001 | <1% | 13 | $230.87 | |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | <1% | 44 | $191.14 |
| 86258 | <1% | 12 | $188.89 | |
| 86364 | <1% | 12 | $186.12 | |
| 80177 | <1% | 16 | $177.64 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 423 | $173.79 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 103 | $162.55 |
| 86231 | <1% | 12 | $149.40 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 450 | $143.11 |
| 86038 | <1% | 14 | $139.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 173 | $119.71 |
| 84436 | <1% | 28 | $100.48 | |
| 84479 | <1% | 27 | $79.82 | |
| 86308 | <1% | 12 | $73.13 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 64 | $70.81 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 321 | $66.02 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 171 | $60.35 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 73 | $51.16 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 41 | $40.55 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 36 | $39.32 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 44 | $22.79 |
| 82784 | <1% | 12 | $9.49 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $5.16 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 17 | $4.16 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 282 | $1.02 |
| A9270 | Non-covered item or service | 0% | 258 | $0.00 |
| 84132 | 0% | 14 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,304 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 34 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.